EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome

L Andreoli, G K Bertsias, N Agmon-Levin, S Brown, R Cervera, N Costedoat-Chalumeau, A Doria, R Fischer-Betz, F Forger, M F Moraes-Fontes, M Khamashta, J King, A Lojacono, F Marchiori, P L Meroni, M Mosca, M Motta, M Ostensen, C Pamfil, L Raio, M Schneider, E Svenungsson, M Tektonidou, S Yavuz, D Boumpas, A Tincani, L Andreoli, G K Bertsias, N Agmon-Levin, S Brown, R Cervera, N Costedoat-Chalumeau, A Doria, R Fischer-Betz, F Forger, M F Moraes-Fontes, M Khamashta, J King, A Lojacono, F Marchiori, P L Meroni, M Mosca, M Motta, M Ostensen, C Pamfil, L Raio, M Schneider, E Svenungsson, M Tektonidou, S Yavuz, D Boumpas, A Tincani

Abstract

Objectives: Develop recommendations for women's health issues and family planning in systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS).

Methods: Systematic review of evidence followed by modified Delphi method to compile questions, elicit expert opinions and reach consensus.

Results: Family planning should be discussed as early as possible after diagnosis. Most women can have successful pregnancies and measures can be taken to reduce the risks of adverse maternal or fetal outcomes. Risk stratification includes disease activity, autoantibody profile, previous vascular and pregnancy morbidity, hypertension and the use of drugs (emphasis on benefits from hydroxychloroquine and antiplatelets/anticoagulants). Hormonal contraception and menopause replacement therapy can be used in patients with stable/inactive disease and low risk of thrombosis. Fertility preservation with gonadotropin-releasing hormone analogues should be considered prior to the use of alkylating agents. Assisted reproduction techniques can be safely used in patients with stable/inactive disease; patients with positive antiphospholipid antibodies/APS should receive anticoagulation and/or low-dose aspirin. Assessment of disease activity, renal function and serological markers is important for diagnosing disease flares and monitoring for obstetrical adverse outcomes. Fetal monitoring includes Doppler ultrasonography and fetal biometry, particularly in the third trimester, to screen for placental insufficiency and small for gestational age fetuses. Screening for gynaecological malignancies is similar to the general population, with increased vigilance for cervical premalignant lesions if exposed to immunosuppressive drugs. Human papillomavirus immunisation can be used in women with stable/inactive disease.

Conclusions: Recommendations for women's health issues in SLE and/or APS were developed using an evidence-based approach followed by expert consensus.

Keywords: Antiphospholipid Antibodies; Antiphospholipid Syndrome; Multidisciplinary team-care; Systemic Lupus Erythematosus; Ultrasonography.

Conflict of interest statement

Competing interests: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

References

    1. Østensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:219–32. 10.1016/j.berh.2004.01.002
    1. Ntali S, Damjanov N, Drakakis P, et al. . Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert Meeting. Clin Exp Rheumatol 2014;32: 959–68.
    1. Kavanaugh A, Cush JJ, Ahmed MS, et al. . Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken) 2015;67:313–25. 10.1002/acr.22516
    1. Østensen M, Andreoli L, Brucato A, et al. . State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 2015;14:376–86. 10.1016/j.autrev.2014.12.011
    1. van der Heijde D, Aletaha D, Carmona L, et al. . 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8–13. 10.1136/annrheumdis-2014-206350
    1. Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306. 10.1111/j.1538-7836.2006.01753.x
    1. Nalli C, Iodice A, Andreoli L, et al. . The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus 2014;23:507–17. 10.1177/0961203313501402
    1. Andreoli L, Fredi M, Nalli C, et al. . Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 2012;38:J197–208. 10.1016/j.jaut.2011.11.010
    1. Parke A. Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases. Lupus 2006;15:808–13. 10.1177/0961203306071003
    1. Vinet É, Pineau CA, Clarke AE, et al. . Neurodevelopmental disorders in children born to mothers with systemic lupus erythematosus. Lupus 2014;23:1099–104. 10.1177/0961203314541691
    1. Nalli C, Iodice A, Andreoli L, et al. . Children born to SLE and APS mothers. Lupus 2014;23:1246–8. 10.1177/0961203314538109
    1. Mekinian A, Lachassinne E, Nicaise-Roland P, et al. . European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 2013;72:217–22. 10.1136/annrheumdis-2011-201167
    1. Vinet É, Pineau CA, Clarke AE, et al. . Increased risk of autism spectrum disorders in children born to women with systemic lupus erythematosus: results from a large population-based cohort. Arthritis Rheumatol 2015;67:3201–8. 10.1002/art.39320
    1. Yang H, Liu H, Xu D, et al. . Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares—a case control study. PLoS ONE 2014;9:e104375 10.1371/journal.pone.0104375
    1. Kwok LW, Tam LS, Zhu T, et al. . Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011;20:829–36. 10.1177/0961203310397967
    1. Roberge S, Giguère Y, Villa P, et al. . Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012;29:551–6. 10.1055/s-0032-1310527
    1. Chen TK, Gelber AC, Witter FR, et al. . Renal biopsy in the management of lupus nephritis during pregnancy. Lupus 2015;24:147–54. 10.1177/0961203314551812
    1. Le Thi Huong D, Wechsler B, Piette JC, et al. . Pregnancy and its outcome in systemic lupus erythematosus. QJM 1994;87:721–9. 10.1093/oxfordjournals.qjmed.a068889
    1. Buyon JP, Kim MY, Guerra MM, et al. . Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015;163:153–63. 10.7326/M14-2235
    1. Clowse ME, Magder LS, Witter F, et al. . The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514–21. 10.1002/art.20864
    1. Mok MY, Leung PY, Lao TH, et al. . Clinical predictors of fetal and maternal outcome in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1705–6. 10.1136/ard.2004.022442
    1. Chakravarty EF, Colón I, Langen ES, et al. . Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897–904. 10.1016/j.ajog.2005.02.063
    1. Imbasciati E, Tincani A, Gregorini G, et al. . Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009;24:519–25. 10.1093/ndt/gfn348
    1. Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus 2010;19:1665–73. 10.1177/0961203310378669
    1. Smyth A, Oliveira GH, Lahr BD, et al. . A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060–8. 10.2215/CJN.00240110
    1. Shibata S, Sasaki T, Hirabayashi Y, et al. . Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis. Ann Rheum Dis 1992;51:619–23. 10.1136/ard.51.5.619
    1. Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. . Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41:643–50. 10.1093/rheumatology/41.6.643
    1. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. . Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014;123:404–13. 10.1182/blood-2013-08-522623
    1. Jeremic K, Stefanovic A, Dotlic J, et al. . Neonatal outcome in pregnant patients with antiphospholipid syndrome. J Perinat Med 2015;43:761–8. 10.1515/jpm-2014-0118
    1. Girón-González JA, García del Río E, Rodríguez C, et al. . Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004;31:1560–7.
    1. Ruffatti A, Tonello M, Visentin MS, et al. . Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011;50:1684–9. 10.1093/rheumatology/ker139
    1. Danowski A, de Azevedo MN, de Souza Papi JA, et al. . Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009;36:1195–9. 10.3899/jrheum.081194
    1. Clowse ME, Magder L, Witter F, et al. . Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640–7. 10.1002/art.22159
    1. Lockshin MD, Kim M, Laskin CA, et al. . Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311–18. 10.1002/art.34402
    1. Stone S, Hunt BJ, Khamashta MA, et al. . Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 2005;3:243–5. 10.1111/j.1538-7836.2005.01185.x
    1. Abou-Nassar K, Carrier M, Ramsay T, et al. . The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011;128:77–85. 10.1016/j.thromres.2011.02.006
    1. Chauleur C, Galanaud JP, Alonso S, et al. . Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010;8:699–706. 10.1111/j.1538-7836.2010.03747.x
    1. Ruffatti A, Calligaro A, Hoxha A, et al. . Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010;62:302–7. 10.1002/acr.20098
    1. Simchen MJ, Dulitzki M, Rofe G, et al. . High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011;90:1428–33. 10.1111/j.1600-0412.2011.01236.x
    1. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. . Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76–82. 10.1161/CIRCULATIONAHA.111.089268
    1. Brucato A, Frassi M, Franceschini F, et al. . Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832–5. 10.1002/1529-0131(200108)44:8<1832::AID-ART320>;2-C
    1. Cimaz R, Spence DL, Hornberger L, et al. . Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003;142:678–83. 10.1067/mpd.2003.233
    1. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. . Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004;50:3187–94. 10.1002/art.20554
    1. Barnado A, Wheless L, Meyer AK, et al. . Pregnancy outcomes among African-American patients with systemic lupus erythematosus compared with controls. Lupus Sci Med 2014;1:e000020 10.1136/lupus-2014-000020
    1. Andrade RM, McGwin G Jr, Alarcón GS, et al. . Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). Rheumatology (Oxford) 2006;45:1380–4. 10.1093/rheumatology/kel222
    1. Lv J, Wang W, Li Y. Clinical outcomes and predictors of fetal and maternal consequences of pregnancy in lupus nephritis patients. Int Urol Nephrol 2015;47:1379–85. 10.1007/s11255-015-1032-y
    1. Moore LE. Recurrent risk of adverse pregnancy outcome. Obstet Gynecol Clin North Am 2008;35:459–71.
    1. Borella E, Lojacono A, Gatto M, et al. . Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res 2014;60:170–6. 10.1007/s12026-014-8572-6
    1. Molad Y, Borkowski T, Monselise A, et al. . Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies. Lupus 2005;14:145–51. 10.1191/0961203305lu2072oa
    1. Stagnaro-Green A, Akhter E, Yim C, et al. . Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery. Lupus 2011;20:690–9. 10.1177/0961203310394894
    1. Shand AW, Algert CS, March L, et al. . Second pregnancy outcomes for women with systemic lupus erythematosus. Ann Rheum Dis 2013;72:547–51. 10.1136/annrheumdis-2011-201210
    1. Bramham K, Hunt BJ, Bewley S, et al. . Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol 2011;38:1906–13. 10.3899/jrheum.100997
    1. Cervera R, Piette JC, Font J, et al. . Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–27. 10.1002/art.10187
    1. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. . The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2015;14:387–95. 10.1016/j.autrev.2014.12.010
    1. Liu LL, Jiang Y, Wang LN, et al. . Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012;72:1521–33. 10.2165/11635030-000000000-00000
    1. Koh JH, Ko HS, Kwok SK, et al. . Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015;24:210–17. 10.1177/0961203314555352
    1. Wagner SJ, Craici I, Reed D, et al. . Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 2009;18:342–7. 10.1177/0961203308097575
    1. Clark CA, Spitzer KA, Nadler JN, et al. . Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127–32.
    1. Fischer-Betz R, Specker C, Brinks R, et al. . Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013;52: 1070–6. 10.1093/rheumatology/kes425
    1. Levy RA, Vilela VS, Cataldo MJ, et al. . Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401–4. 10.1191/096120301678646137
    1. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone Geneva: World Health Organization, 2010.
    1. Pisoni CN, Cuadrado MJ, Khamashta MA, et al. . Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006;15:877–80. 10.1177/0961203306071706
    1. Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8. 10.1056/NEJMoa051135
    1. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. . A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539–49. 10.1056/NEJMoa050817
    1. Urbanus RT, Siegerink B, Roest M, et al. . Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009;8:998–1005. 10.1016/S1474-4422(09)70239-X
    1. Clowse ME, Chakravarty E, Costenbader KH, et al. . Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:668–74. 10.1002/acr.21593
    1. Ekblom-Kullberg S, Kautiainen H, Alha P, et al. . Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol 2009;38:375–80. 10.1080/03009740902763099
    1. Morel N, Bachelot A, Chakhtoura Z, et al. . Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013;98:3785–92. 10.1210/jc.2013-1235
    1. Velarde-Ochoa Mdel C, Esquivel-Valerio JA, Vega-Morales D, et al. . Anti-Müllerian hormone in reproductive age women with systemic lupus erythematosus. Reumatol Clin 2015;11:78–82. 10.1016/j.reuma.2014.03.009
    1. Boumpas DT, Austin HA III, Vaughan EM, et al. . Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366–9. 10.7326/0003-4819-119-5-199309010-00003
    1. Ioannidis JP, Katsifis GE, Tzioufas AG, et al. . Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002;29:2129–35.
    1. Houssiau FA, Vasconcelos C, D'Cruz D, et al. . The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61–4. 10.1136/ard.2008.102533
    1. Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2015;103:e44–50. 10.1016/j.fertnstert.2015.03.019
    1. Henes M, Henes JC, Neunhoeffer E, et al. . Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus 2012;21:953–8. 10.1177/0961203312442753
    1. Elizur SE, Chian RC, Pineau CA, et al. . Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford) 2008;47:1506–9. 10.1093/rheumatology/ken293
    1. Ben-Aharon I, Gafter-Gvili A, Leibovici L, et al. . Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803–11. 10.1007/s10549-010-0996-7
    1. Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncologist 2015;20:1283–9. 10.1634/theoncologist.2015-0223
    1. Moore HC, Unger JM, Phillips KA, et al. . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923–32. 10.1056/NEJMoa1413204
    1. Brunner HI, Silva CA, Reiff A, et al. . Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2015;67:1377–85. 10.1002/art.39024
    1. Guballa N, Sammaritano L, Schwartzman S, et al. . Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000;43:550–6. 10.1002/1529-0131(200003)43:3<550::AID-ANR10>;2-Y
    1. Huong DL, Wechsler B, Vauthier-Brouzes D, et al. . Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum 2002;32:174–88. 10.1053/sarh.2002.37212
    1. Ragab A, Barakat R, Ragheb M, et al. . Subfertility treatment in women with systemic lupus erythematosus. J Obstet Gynaecol 2012;32:569–71. 10.3109/01443615.2012.693986
    1. Orquevaux P, Masseau A, Le Guern V, et al. . [In vitro fertilization and systemic lupus erythematosus or antiphospholipid syndrome: an update]. Rev Med Interne 2015;36:154–8. 10.1016/j.revmed.2014.08.004
    1. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril 2009;92:1803–10. 10.1016/j.fertnstert.2009.06.033
    1. Ruiz-Irastorza G, Khamashta MA, Gordon C, et al. . Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004;51:78–82. 10.1002/art.20081
    1. Yee CS, Akil M, Khamashta M, et al. . The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. Rheumatology (Oxford) 2012;51:1877–80. 10.1093/rheumatology/kes158
    1. Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol 2004;18:359–79. 10.1016/j.berh.2004.02.012
    1. Buyon JP, Cronstein BN, Morris M, et al. . Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986;81:194–200. 10.1016/0002-9343(86)90251-2
    1. Tomer Y, Viegas OA, Swissa M, et al. . Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol 1996;14:275–80.
    1. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011;38:1012–16. 10.3899/jrheum.100746
    1. Kobayashi N, Yamada H, Kishida T, et al. . Hypocomplementemia correlates with intrauterine growth retardation in systemic lupus erythematosus. Am J Reprod Immunol 1999;42:153–9. 10.1111/j.1600-0897.1999.tb00479.x
    1. Clowse ME, Wallace DJ, Weisman M, et al. . Predictors of preterm birth in patients with mild systemic lupus erythematosus. Ann Rheum Dis 2013;72:1536–9. 10.1136/annrheumdis-2012-202449
    1. Lees C, Marlow N, Arabin B, et al. . Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol 2013;42:400–8. 10.1002/uog.13190
    1. Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. . 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet 2015;385:2162–72. 10.1016/S0140-6736(14)62049-3
    1. Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2013;11:CD007529 10.1002/14651858.CD007529.pub3
    1. Figueras F, Savchev S, Triunfo S, et al. . An integrated model with classification criteria to predict small-for-gestational-age fetuses at risk of adverse perinatal outcome. Ultrasound Obstet Gynecol 2015;45:279–85. 10.1002/uog.14714
    1. Sovio U, White IR, Dacey A, et al. . Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet 2015;386:2089–97. 10.1016/S0140-6736(15)00131-2
    1. Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. . The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301–12. 10.1038/nrrheum.2015.29
    1. Saxena A, Izmirly PM, Mendez B, et al. . Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev 2014;22:263–7. 10.1097/CRD.0000000000000026
    1. Friedman DM, Kim MY, Copel JA, et al. . Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009;103:1102–6. 10.1016/j.amjcard.2008.12.027
    1. Izmirly PM, Saxena A, Kim MY, et al. . Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011;124:1927–35. 10.1161/CIRCULATIONAHA.111.033894
    1. Eliasson H, Sonesson SE, Sharland G, et al. . Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011;124:1919–26. 10.1161/CIRCULATIONAHA.111.041970
    1. Levesque K, Morel N, Maltret A, et al. . Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015;14:1154–60. 10.1016/j.autrev.2015.08.005
    1. Izmirly PM, Saxena A, Sahl SK, et al. . Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016;75:1161-5. 10.1136/annrheumdis-2015-208311
    1. Tingström J, Hjelmstedt A, Welin Henriksson E, et al. . Ro/SSA autoantibody-positive pregnancy: reactions to serial fetal Doppler echocardiographic surveillance. Lupus 2015;24:1540–5. 10.1177/0961203315593171
    1. Derksen RH, Bruinse HW, de Groot PG, et al. . Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 1994;3:149–55. 10.1177/096120339400300304
    1. Al Maimouni H, Gladman DD, Ibañez D, et al. . Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. Arthritis Care Res (Hoboken) 2014;66:1905–9. 10.1002/acr.22364
    1. Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993;40:160–3.
    1. Webster P, Wardle A, Bramham K, et al. . Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014;23:1192–6. 10.1177/0961203314540353
    1. Moroni G, Quaglini S, Banfi G, et al. . Pregnancy in lupus nephritis. Am J Kidney Dis 2002;40:713–20. 10.1053/ajkd.2002.35678
    1. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. . The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810. 10.1136/annrheumdis-2015-208840
    1. Abou-Nassar K, Karsh J, Giulivi A, et al. . Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss. Transfus Apher Sci 2010;43:29–31. 10.1016/j.transci.2010.05.002
    1. Takeshita Y, Turumi Y, Touma S, et al. . Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis. Ther Apher 2001;5:22–4. 10.1046/j.1526-0968.2001.005001022.x
    1. Cavallasca JA, Laborde HA, Ruda-Vega H, et al. . Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE). Clin Rheumatol 2008;27:41–6. 10.1007/s10067-007-0649-3
    1. Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum 2014;44:195–7. 10.1016/j.semarthrit.2014.05.006
    1. Østensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol 2013;13:470–5. 10.1016/j.coph.2013.03.004
    1. Flint J, Panchal S, Hurrell A, et al. . BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 2016. [epub ahead of print].
    1. Flint J, Panchal S, Hurrell A, et al. . BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology 2016. [epub ahead of print].
    1. Sciascia S, Hunt BJ, Talavera-Garcia E, et al. . The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016;214:273.e1-8. [epub ahead of print] 10.1016/j.ajog.2015.09.078
    1. Sciascia S, Branch DW, Levy RA, et al. . The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 2016;115:285–90. 10.1160/TH15-06-0491
    1. Mekinian A, Lazzaroni MG, Kuzenko A, et al. . The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015;14:498–502. 10.1016/j.autrev.2015.01.012
    1. Tunks RD, Clowse ME, Miller SG, et al. . Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol 2013;208:64.e1-7. 10.1016/j.ajog.2012.09.020
    1. Roberge S, Villa P, Nicolaides K, et al. . Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6. 10.1159/000336662
    1. Wu CQ, Kustec VE, Brown RN, et al. . The medical management of antiphospholipid syndrome in pregnancy: a meta-analysis. Obstet Gynecol 2014;123(Suppl 1):178s–9s.
    1. Mak A, Cheung MW, Cheak AA, et al. . Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010;49:281–8. 10.1093/rheumatology/kep373
    1. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256–62. 10.1097/AOG.0b013e3181deba40
    1. de Jesús GR, Rodrigues G, de Jesús NR, et al. . Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 2014;16:403 10.1007/s11926-013-0403-6
    1. Ruffatti A, Gervasi MT, Favaro M, et al. . Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Clin Exp Rheumatol 2011;29:551–4.
    1. Fouda UM, Sayed AM, Abdou AM, et al. . Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet 2011;112:211–15. 10.1016/j.ijgo.2010.09.010
    1. Ruffatti A, Salvan E, Del Ross T, et al. . Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 2014;112:727–35. 10.1160/TH14-03-0191
    1. Bramham K, Thomas M, Nelson-Piercy C, et al. . First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011;117:6948–51. 10.1182/blood-2011-02-339234
    1. Fischer-Betz R, Specker C, Brinks R, et al. . Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 2012;21:1183–9. 10.1177/0961203312451335
    1. Le Thi Thuong D, Tieulié N, Costedoat N, et al. . The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005;64:273–8. 10.1136/ard.2003.019000
    1. Buyon JP, Petri MA, Kim MY, et al. . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142(Pt 1):953–62. 10.7326/0003-4819-142-12_Part_1-200506210-00004
    1. Sánchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. . Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007;56:3070–9. 10.1002/art.22855
    1. Cravioto MD, Durand-Carbajal M, Jiménez-Santana L, et al. . Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial. Arthritis Care Res (Hoboken) 2011;63:1654–63. 10.1002/acr.20608
    1. Hochman J, Urowitz MB, Ibañez D, et al. . Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Lupus 2009;18:313–17. 10.1177/0961203308097475
    1. Fernandez M, Calvo-Alen J, Bertoli AM, et al. . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 2007;13:261–5. 10.1097/RHU.0b013e318156bbf5
    1. Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther 2015;37:1837–50. 10.1016/j.clinthera.2015.06.006
    1. Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015;351:h5746 10.1136/bmj.h5746
    1. National Collaborating Centre for Ws, Children's H. National Institute for Health and Clinical Excellence: Guidance. Menopause: Full Guideline London: National Institute for Health and Care Excellence (UK) Copyright (c) 2015 National Collaborating Centre for Women's and Children's Health, 2015.
    1. Bernatsky S, Ramsey-Goldman R, Foulkes WD, et al. . Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 2011;104:1478–81. 10.1038/bjc.2011.115
    1. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. . Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130–5. 10.1016/j.jaut.2012.12.009
    1. Liu H, Ding Q, Yang K, et al. . Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford) 2011;50:343–8. 10.1093/rheumatology/keq304
    1. Santana IU, Gomes Ado N, Lyrio LD, et al. . Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011;30:665–72. 10.1007/s10067-010-1606-0
    1. Zard E, Arnaud L, Mathian A, et al. . Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev 2014;13:730–5. 10.1016/j.autrev.2014.03.001
    1. Dreyer L, Faurschou M, Mogensen M, et al. . High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011;63:3032–7. 10.1002/art.30483
    1. Bateman H, Yazici Y, Leff L, et al. . Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000;9:542–4. 10.1177/096120330000900711
    1. Bernatsky S, Ramsey-Goldman R, Gordon C, et al. . Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:1386–9. 10.1093/rheumatology/keh331
    1. Ognenovski VM, Marder W, Somers EC, et al. . Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763–7.
    1. Klumb EM, Araujo ML Jr, Jesus GR, et al. . Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol 2010;16:153–7. 10.1097/RHU.0b013e3181df5261
    1. Bernatsky SR, Cooper GS, Mill C, et al. . Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 2006;33:45–9.
    1. Yazdany J, Tonner C, Trupin L, et al. . Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther 2010;12:R84 10.1186/ar3011
    1. Slade BA, Leidel L, Vellozzi C, et al. . Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750–7. 10.1001/jama.2009.1201
    1. Soybilgic A, Onel KB, Utset T, et al. . Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013;11:29 10.1186/1546-0096-11-29
    1. Mok CC, Ho LY, Fong LS, et al. . Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013;72:659–64. 10.1136/annrheumdis-2012-201393
    1. Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21:158–61. 10.1177/0961203311429556
    1. Gatto M, Agmon-Levin N, Soriano A, et al. . Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013;32:1301–7. 10.1007/s10067-013-2266-7
    1. Baker B, Eça Guimarães L, Tomljenovic L, et al. . The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 2015;14:1387–94. 10.1517/14740338.2015.1073710
    1. van Assen S, Agmon-Levin N, Elkayam O, et al. . EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414–22. 10.1136/ard.2010.137216

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj